Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
6 "Yong-Sang Song"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Gynecologic cancer
Effect of BRCA1/2 Mutational Status on Survival Outcomes According to Secondary Cytoreductive Surgery and Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer: A Real-World Evidence Study
Se Ik Kim, Hyunji Lim, Hee Seung Kim, Hyun Hoon Chung, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song, Maria Lee
Cancer Res Treat. 2023;55(1):245-257.   Published online July 19, 2022
DOI: https://doi.org/10.4143/crt.2022.232
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to investigate the impact of BRCA1/2 mutational status on survival outcomes in patients with platinum-sensitive relapsed (PSR) epithelial ovarian cancer (EOC).
Materials and Methods
We retrospectively identified patients who received secondary treatment for PSR EOC at our institution between January 2007 and June 2021 and who underwent BRCA1/2 gene testing by either germline or somatic methods. The association between BRCA1/2 mutational status and survival outcomes was evaluated. Both secondary cytoreductive surgery (CRS) and maintenance therapy were stratified considering real-world clinical practice.
Results
Of 262 patients, 91 (34.7%) and 171 (65.3%) were assigned to BRCA1/2 mutation and wild-type groups, respectively. The two groups had similar proportions of patients undergoing secondary CRS (26.4% vs. 32.7%, p=0.286) and maintenance therapy (54.9% vs. 46.2%, p=0.178). Overall, no differences in progression-free survival (PFS; median, 19.7 vs. 15.1 months, p=0.120) and overall survival (OS; p=0.400) were observed between the two groups. In multivariate analyses, BRCA1/2 mutational status was not associated with PFS (adjusted hazard ratio, 0.816; 95% confidence interval, 0.596 to 1.119; p=0.207). BRCA1/2 mutational status did not affect PFS among patients who underwent secondary CRS (n=80) and among those who did not (n=182) (p=0.074 and p=0.222, respectively). PFS did not differ in the BRCA1/2 mutational status among the patients who received bevacizumab maintenance (n=90, p=0.992).
Conclusion
In this real-world evidence study, BRCA1/2 mutational status itself was not associated with PFS and OS in PSR EOC, which was consistent with whether secondary CRS or not and with bevacizumab maintenance.
  • 4,739 View
  • 162 Download
Close layer
Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea
Se Ik Kim, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song
Cancer Res Treat. 2020;52(4):1229-1241.   Published online July 27, 2020
DOI: https://doi.org/10.4143/crt.2020.557
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to present a single institutional experience with BRCA1/2 gene tests and the effects of pathogenic mutations in epithelial peritoneal, ovarian, and fallopian tube cancer (POFTC) on survival outcomes.
Materials and Methods
We identified patients with epithelial POFTCs who underwent BRCA1/2 gene testing by either germline or somatic methods between March 2007 and March 2020. Based on the BRCA1/2 test results, patients were divided into BRCA mutation and wild-type groups, followed by comparisons of clinicopathologic characteristics and survival outcomes after primary treatment.
Results
The annual number of POFTC patients who received BRCA1/2 gene tests increased gradually. In total, 511 patients were included and BRCA1/2 mutations were observed in 143 (28.0%). Among 57 patients who received both germline and somatic tests, three (5.3%) showed discordant results from the two tests. Overall, no differences in progression-free survival (PFS; p=0.467) and overall survival (p=0.641) were observed between the BRCA mutation and wild-type groups; however, multivariate analyses identified BRCA1/2 mutation as an independent favorable prognostic factor for PFS (adjusted hazard ratio [aHR], 0.765; 95% confidence interval [CI], 0.593 to 0.987; p=0.040). In 389 patients with International Federation of Gynecology and Obstetrics stage III-IV, different results were shown depending on primary treatment strategy: while BRCA1/2 mutation significantly improved PFS in the subgroup of neoadjuvant chemotherapy (aHR, 0.619; 95% CI, 0.385 to 0.995; p=0.048), it did not affect patient PFS in the subgroup of primary debulking surgery (aHR, 0.759; 95% CI, 0.530 to 1.089; p=0.135).
Conclusion
BRCA1/2 mutations are frequently observed in patients with epithelial POFTCs, and such patients showed better PFS than did those harboring wild-type BRCA1/2.

Citations

Citations to this article as recorded by  
  • Overview of Molecular Diagnostics in Irish Clinical Oncology
    Tyler Medina, Seán O. Hynes, Maeve Lowery, Paddy Gillespie, Walter Kolch, Cathal Seoighe
    HRB Open Research.2024; 7: 16.     CrossRef
  • Trends in the Incidence and Survival Rates of Primary Ovarian Clear Cell Carcinoma Compared to Ovarian Serous Carcinoma in Korea
    Se Ik Kim, Hyeong In Ha, Kyung Jin Eoh, Jiwon Lim, Young-Joo Won, Myong Cheol Lim
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Characteristics of homologous recombination repair pathway genes mutation in ovarian cancers
    Zongbi Yi, Min Chen, Shaoxing Sun, Chunxu Yang, Zijie Mei, Hui Yang, Qingming Xiang, Hui Qiu
    Cancer Innovation.2022; 1(3): 220.     CrossRef
  • 8,122 View
  • 214 Download
  • 12 Web of Science
  • 3 Crossref
Close layer
Development of Web-Based Nomograms to Predict Treatment Response and Prognosis of Epithelial Ovarian Cancer
Se Ik Kim, Minsun Song, Suhyun Hwangbo, Sungyoung Lee, Untack Cho, Ju-Hyun Kim, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Dae-Shik Suh, Taesung Park, Yong-Sang Song
Cancer Res Treat. 2019;51(3):1144-1155.   Published online November 20, 2018
DOI: https://doi.org/10.4143/crt.2018.508
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Discovery of models predicting the exact prognosis of epithelial ovarian cancer (EOC) is necessary as the first step of implementation of individualized treatment. This study aimed to develop nomograms predicting treatment response and prognosis in EOC.
Materials and Methods
We comprehensively reviewed medical records of 866 patients diagnosed with and treated for EOC at two tertiary institutional hospitals between 2007 and 2016. Patients’ clinico-pathologic characteristics, details of primary treatment, intra-operative surgical findings, and survival outcomes were collected. To construct predictive nomograms for platinum sensitivity, 3-year progression-free survival (PFS), and 5-year overall survival (OS), we performed stepwise variable selection by measuring the area under the receiver operating characteristic curve (AUC) with leave-one-out cross-validation. For model validation, 10-fold cross-validation was applied.
Results
The median length of observation was 42.4 months (interquartile range, 25.7 to 69.9 months), during which 441 patients (50.9%) experienced disease recurrence. The median value of PFS was 32.6 months and 3-year PFS rate was 47.8% while 5-year OS rate was 68.4%. The AUCs of the newly developed nomograms predicting platinum sensitivity, 3-year PFS, and 5-year OS were 0.758, 0.841, and 0.805, respectively. We also developed predictive nomograms confined to the patients who underwent primary debulking surgery. The AUCs for platinum sensitivity, 3-year PFS, and 5-year OS were 0.713, 0.839, and 0.803, respectively.
Conclusion
We successfully developed nomograms predicting treatment response and prognosis of patients with EOC. These nomograms are expected to be useful in clinical practice and designing clinical trials.

Citations

Citations to this article as recorded by  
  • Comprehensive analyses of mitophagy-related genes and mitophagy-related lncRNAs for patients with ovarian cancer
    Jianfeng Zheng, Shan Jiang, Xuefen Lin, Huihui Wang, Li Liu, Xintong Cai, Yang Sun
    BMC Women's Health.2024;[Epub]     CrossRef
  • Peripheral and tumor‐infiltrating immune cells are correlated with patient outcomes in ovarian cancer
    Weiwei Zhang, Yawen Ling, Zhidong Li, Xingchen Peng, Yazhou Ren
    Cancer Medicine.2023; 12(8): 10045.     CrossRef
  • Nonalcoholic fatty liver disease and early prediction of gestational diabetes mellitus using machine learning methods
    Seung Mi Lee, Suhyun Hwangbo, Errol R. Norwitz, Ja Nam Koo, Ig Hwan Oh, Eun Saem Choi, Young Mi Jung, Sun Min Kim, Byoung Jae Kim, Sang Youn Kim, Gyoung Min Kim, Won Kim, Sae Kyung Joo, Sue Shin, Chan-Wook Park, Taesung Park, Joong Shin Park
    Clinical and Molecular Hepatology.2022; 28(1): 105.     CrossRef
  • Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives
    Stanislas Quesada, Michel Fabbro, Jérôme Solassol
    Cancers.2022; 14(4): 1098.     CrossRef
  • Construction and validation of a transcription factors-based prognostic signature for ovarian cancer
    Qingyuan Cheng, Liman Li, Mingxia Yu
    Journal of Ovarian Research.2022;[Epub]     CrossRef
  • Predicting preterm birth through vaginal microbiota, cervical length, and WBC using a machine learning model
    Sunwha Park, Jeongsup Moon, Nayeon Kang, Young-Han Kim, Young-Ah You, Eunjin Kwon, AbuZar Ansari, Young Min Hur, Taesung Park, Young Ju Kim
    Frontiers in Microbiology.2022;[Epub]     CrossRef
  • Prognostic nomogram that predicts progression-free survival and overall survival of patients with ovarian clear cell carcinoma
    Jiayi Li, Dongyan Cao
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Recent Advances and Future Directions of Diagnostic and Prognostic Prediction Models in Ovarian Cancer
    Judan Zeng, Wenjiao Cao, Lihua Wang
    Journal of Shanghai Jiaotong University (Science).2021; 26(1): 10.     CrossRef
  • Sphingolipids as multifaceted mediators in ovarian cancer
    MelissaR Pitman, Martin K. Oehler, Stuart M. Pitson
    Cellular Signalling.2021; 81: 109949.     CrossRef
  • Development and validation for prognostic nomogram of epithelial ovarian cancer recurrence based on circulating tumor cells and epithelial–mesenchymal transition
    Jiani Yang, Jun Ma, Yue Jin, Shanshan Cheng, Shan Huang, Nan Zhang, Yu Wang
    Scientific Reports.2021;[Epub]     CrossRef
  • Prediction Models for the Clinical Severity of Patients With COVID-19 in Korea: Retrospective Multicenter Cohort Study
    Bumjo Oh, Suhyun Hwangbo, Taeyeong Jung, Kyungha Min, Chanhee Lee, Catherine Apio, Hyejin Lee, Seungyeoun Lee, Min Kyong Moon, Shin-Woo Kim, Taesung Park
    Journal of Medical Internet Research.2021; 23(4): e25852.     CrossRef
  • Development of Machine Learning Models to Predict Platinum Sensitivity of High-Grade Serous Ovarian Carcinoma
    Suhyun Hwangbo, Se Ik Kim, Ju-Hyun Kim, Kyung Jin Eoh, Chanhee Lee, Young Tae Kim, Dae-Shik Suh, Taesung Park, Yong Sang Song
    Cancers.2021; 13(8): 1875.     CrossRef
  • M2 Macrophage-Based Prognostic Nomogram for Gastric Cancer After Surgical Resection
    Jianwen Hu, Yongchen Ma, Ju Ma, Yanpeng Yang, Yingze Ning, Jing Zhu, Pengyuan Wang, Guowei Chen, Yucun Liu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Prognosis for intrahepatic cholangiocarcinoma patients treated with postoperative adjuvant transcatheter hepatic artery chemoembolization
    Ji-Bin Liu, Kai-Jian Chu, Chang-Chun Ling, Ting-Miao Wu, Hui-Min Wang, Yi Shi, Zhi-Zhen Li, Jing-Han Wang, Zhi-Jun Wu, Xiao-Qing Jiang, Gao-Ren Wang, Yu-Shui Ma, Da Fu
    Current Problems in Cancer.2020; 44(6): 100612.     CrossRef
  • Can we predict who lives long with ovarian cancer?
    Michael A. Bookman
    Cancer.2019; 125(S24): 4578.     CrossRef
  • 10,308 View
  • 266 Download
  • 16 Web of Science
  • 15 Crossref
Close layer
An Alternative Triage Strategy Based on Preoperative MRI for Avoiding Trimodality Therapy in Stage IB Cervical Cancer
Jung-Yun Lee, Jina Youm, Jae Weon Kim, Kidong Kim, Hak Jae Kim, Jeong Yeon Cho, Min A Kim, Noh Hyun Park, Yong-Sang Song
Cancer Res Treat. 2016;48(1):259-265.   Published online March 20, 2015
DOI: https://doi.org/10.4143/crt.2014.370
AbstractAbstract PDFPubReaderePub
Purpose
Adjuvant chemoradiation following primary surgery is frequently indicated in patients with stage IB cervical cancer. The aim of this study is to evaluate the role of a magnetic resonance imaging (MRI)-based strategy in avoiding trimodality therapy.
Materials and Methods
We retrospectively reviewed all patients with stage IB cervical cancer treated initially with primary surgery at Seoul National University Hospital. We suggest an alternative triage strategy in which the primary treatment modality is determined based on preoperative MRI findings. Using this strategy, primary surgery is only indicated when there is no evidence of parametrial involvement (PMI) and lymph node metastasis (LNM) in the MRI results; when there is evidence of either or both of these factors, primary chemoradiation is selected. Assuming that this strategy is applied to our cohort, we evaluate how the rate of trimodality therapy is affected.
Results
Of the 254 patients in our sample, 77 (30.3%) had at least one category 1 risk factor (PMI, LNM, positive resection margin) upon pathologic examination. If the MRI-based strategy had been applied to our cohort, 168 patients would have undergone primary surgery and 86 would have undergone primary chemoradiation. Only 25 patients (9.8%) would have required trimodality therapy based on an indication of at least one category 1 pathologic risk factor following radical hysterectomy.
Conclusion
The inclusion of MRI in the decision-making process for primary treatment modality could have reduced the number of patients requiring trimodality therapy based on the indication of a category 1 risk factor from 30.3% to 9.8% in our cohort.

Citations

Citations to this article as recorded by  
  • Deep-learning-based radiomics of intratumoral and peritumoral MRI images to predict the pathological features of adjuvant radiotherapy in early-stage cervical squamous cell carcinoma
    Xue-Fang Zhang, Hong-yuan Wu, Xu-Wei Liang, Jia-Luo Chen, Jianpeng Li, Shihao Zhang, Zhigang Liu
    BMC Women's Health.2024;[Epub]     CrossRef
  • Definitive Chemoradiotherapy versus Radical Hysterectomy Followed by Tailored Adjuvant Therapy in Women with Early-Stage Cervical Cancer Presenting with Pelvic Lymph Node Metastasis on Pretreatment Evaluation: A Propensity Score Matching Analysis
    Jongmoo Park, Yeon-Joo Kim, Mi-Kyung Song, Joo-Hyun Nam, Sang-Yoon Park, Young-Seok Kim, Joo-Young Kim
    Cancers.2021; 13(15): 3703.     CrossRef
  • Quality of life among survivors of early-stage cervical cancer in Taiwan: an exploration of treatment modality differences
    Chia-Chun Li, Ting-Chang Chang, Yun-Fang Tsai, Lynn Chen
    Quality of Life Research.2017; 26(10): 2773.     CrossRef
  • Parametrial Involvement on Magnetic ResonanceImaging Has No Effect on the Survival of Early-StageCervical Cancer Patients
    Kyungmi Yang, Won Park, Seung Jae Huh, Byung Kwan Park, Chan Kyo Kim, Byoung-Gie Kim, Duk-Soo Bae, Jeong-Won Lee
    International Journal of Gynecological Cancer.2017; 27(3): 507.     CrossRef
  • Treatment strategies for stage IB cervical cancer: A cost-effectiveness analysis from Korean, Canadian and US perspectives
    Jung-Yun Lee, Janice S. Kwon, David E. Cohn, Younhee Kim, Blair Smith, Tae-Jin Lee, Jae-Weon Kim
    Gynecologic Oncology.2016; 140(1): 83.     CrossRef
  • 12,309 View
  • 85 Download
  • 4 Web of Science
  • 5 Crossref
Close layer
Safety of Fertility-Sparing Surgery in Primary Mucinous Carcinoma of the Ovary
Jung-Yun Lee, Yu Ri Jo, Tae Hun Kim, Hee Seung Kim, Min A Kim, Jae Weon Kim, Noh Hyun Park, Yong-Sang Song
Cancer Res Treat. 2015;47(2):290-305.   Published online August 29, 2014
DOI: https://doi.org/10.4143/crt.2014.004
AbstractAbstract PDFPubReaderePub
Purpose
The aim of this study is to evaluate the safety of fertility-sparing surgery as the treatment for patients with primary mucinous epithelial ovarian cancer.
Materials and Methods
A retrospective study of patients with mucinous ovarian cancer between 1991 and 2010 was performed. The demographics and survival outcomes were compared between patients who underwent fertility-sparing surgery and those who underwent radical surgery.
Results
A total of 110 patients underwent primary surgery. At the time of surgery, tumors appeared to be grossly confined to the ovaries in 90 patients, and evidence of metastasis was definite in 20 patients. Of the 90 patients with tumors that appeared to be grossly confined to the ovaries at surgical exploration, 35 (38.9%) underwent fertility-sparing surgery. The Kaplan- Meier curve and the log rank test showed no difference in either recurrence-free survival (p=0.792) or disease-specific survival (p=0.706) between the two groups. Furthermore, there was no significant difference in recurrence-free survival (p=0.126) or disease-specific survival (p=0.377) between the two groups, even when the analysis was limited to women below the age of 40. In a multivariate Cox model, fertility-sparing surgery had no effect on either recurrence-free survival (recurrence hazard ratio [HR], 1.20; 95% confidence interval [CI], 0.25 to 5.71) or disease-specific survival (death HR, 0.88; 95% CI, 0.17 to 4.60).
Conclusion
Fertility-sparing surgery in primary mucinous cancer grossly confined to the ovaries may be a safe option and one not associated with an increase in recurrence or mortality.

Citations

Citations to this article as recorded by  
  • A Complex Case: Solid Unilateral Ovarian Mucinous Carcinoma Masquerading as Leiomyosarcoma in Postmenopausal Women
    Naina Kumar, Immanuel Pradeep, Mishu Mangla, Annapurna Srirambhatla
    Current Womens Health Reviews.2025;[Epub]     CrossRef
  • Prognosis of stage-I ovarian mucinous tumors according to expansile and infiltrative types
    Malek Bouhani, Stéphanie Schérier, Catherine Genestie, Mojgan Devouassoux-Shisheboran, Amandine Maulard, Francois Zaccarini, Alexandra Leary, Patricia Pautier, Philippe Morice, Sébastien Gouy
    International Journal of Gynecological Cancer.2025; : 101641.     CrossRef
  • Controversies in the management of mucinous ovarian tumors
    Félix Blanc-Durand, Alexandra Leary
    International Journal of Gynecological Cancer.2025; 35(3): 101679.     CrossRef
  • Safety of fertility-sparing surgery in young women with stage I endometrioid epithelial and mucinous ovarian cancer: A population-based analysis
    Jing Li, Huimin Qiao, Yunyun Liu, Chunxian Huang, Aoshuang Cheng, Zhongqiu Lin, Lijuan Wang, Huaiwu Lu
    European Journal of Surgical Oncology.2024; 50(1): 107276.     CrossRef
  • Mucinous ovarian carcinoma: A survey of practice in Australia and New Zealand
    Niveditha Rajadevan, Ariane Flinkier, Hugo Saunders, Yeh Chen Lee, Clare Scott, Pearly Khaw, Prue Allan, Claire Davies, John Andrews, Michelle Wilson, Janine M Lombard, Michelle Harrison, Heshani Nesfield, Anna DeFazio, Tarek Meniawy, Kylie L Gorringe
    Australian and New Zealand Journal of Obstetrics and Gynaecology.2024; 64(4): 319.     CrossRef
  • Evaluation of Outcomes of Mucinous Ovarian Cancer Treated at a Tertiary Care Cancer Hospital in Pakistan
    Syed Abdul Mannan Hamdani, Musa Azhar, Abdul Wahab, Tahira Yasmeen, Neelam Siddiqui
    South Asian Journal of Cancer.2023; 12(01): 081.     CrossRef
  • Update on Prognostic and Predictive Markers in Mucinous Ovarian Cancer
    Fulvio Borella, Marco Mitidieri, Stefano Cosma, Chiara Benedetto, Luca Bertero, Stefano Fucina, Isabelle Ray-Coquard, Annalisa Carapezzi, Domenico Ferraioli
    Cancers.2023; 15(4): 1172.     CrossRef
  • Safety of fertility sparing management in invasive mucinous ovarian carcinoma
    Soyoun Rachel Kim, Ainhoa Madariaga, Liat Hogen, Danielle Vicus, Allan Covens, Carlos Parra-Herran, Stephanie Lheureux, Lilian T. Gien
    Gynecologic Oncology.2023; 174: 129.     CrossRef
  • Rare Epithelial Ovarian Cancers: Low Grade Serous and Mucinous Carcinomas
    Olivia Craig, Abhimanyu Nigam, Genevieve V. Dall, Kylie Gorringe
    Cold Spring Harbor Perspectives in Medicine.2023; 13(9): a038190.     CrossRef
  • Oncological and Reproductive Outcomes After Fertility-Sparing Surgery for Stage I Mucinous Ovarian Carcinoma
    Wei Lin, Dongyan Cao, Xiaohua Shi, Yan You, Jiaxin Yang, Keng Shen
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Surgical treatment for clinical early-stage expansile and infiltrative mucinous ovarian cancer: can staging surgeries safely be omitted?
    Marc D. Algera, Willemien J. van Driel, Koen K. van de Vijver, Roy F.P.M. Kruitwagen, Christianne A.R. Lok
    Current Opinion in Oncology.2022; 34(5): 497.     CrossRef
  • Primary mucinous ovarian cancer: options for surgery and chemotherapy
    Katherine C Kurnit, Michael Frumovitz
    International Journal of Gynecological Cancer.2022; 32(11): 1455.     CrossRef
  • Outcomes after Fertility-sparing Surgery for Women with Ovarian Cancer: A Systematic Review of the Literature
    Alexandra Bercow, Roni Nitecki, Paula C. Brady, J.Alejandro Rauh-Hain
    Journal of Minimally Invasive Gynecology.2021; 28(3): 527.     CrossRef
  • Fertility preserving surgery in carcinoma ovary: a single institution experience
    T. Subramanyeshwar Rao, KVVN Raju, Vikas Gupta, R. Rajagopalan Iyer
    Indian Journal of Gynecologic Oncology.2021;[Epub]     CrossRef
  • Fertility-Sparing Surgery in Gynecologic Cancer: A Systematic Review
    Teska Schuurman, Sanne Zilver, Sanne Samuels, Winnie Schats, Frédéric Amant, Nienke van Trommel, Christianne Lok
    Cancers.2021; 13(5): 1008.     CrossRef
  • Fertility preservation in rare ovarian tumors
    Anca Chelariu-Raicu, Lauren P Cobb, David M Gershenson
    International Journal of Gynecological Cancer.2021; 31(3): 432.     CrossRef
  • Oncologic outcomes of uterine preservation for pre-menopausal patients with stage II epithelial ovarian carcinoma
    Dimitrios Nasioudis, Lakeisha Mulugeta-Gordon, Erin McMinn, Maureen Byrne, Emily M Ko, Lori Cory, Ashley F Haggerty, Nawar A Latif
    International Journal of Gynecological Cancer.2021; 31(3): 480.     CrossRef
  • Fertility-Sparing Surgery for Ovarian Cancer
    Geoffroy Canlorbe, Nathalie Chabbert-Buffet, Catherine Uzan
    Journal of Clinical Medicine.2021; 10(18): 4235.     CrossRef
  • Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors
    M. Bartoletti, L. Musacchio, G. Giannone, V. Tuninetti, A. Bergamini, G. Scambia, D. Lorusso, G. Valabrega, G. Mangili, F. Puglisi, S. Pignata
    Cancer Treatment Reviews.2021; 101: 102298.     CrossRef
  • Options for the Treatment of Mucinous Ovarian Carcinoma
    Olivia Craig, Carolina Salazar, Kylie L. Gorringe
    Current Treatment Options in Oncology.2021;[Epub]     CrossRef
  • Fertility sparing surgery vs radical surgery for epithelial ovarian cancer: a meta-analysis of overall survival and disease-free survival
    Denghua Liu, Jing Cai, Aiwei Gao, Zehua Wang, Liqiong Cai
    BMC Cancer.2020;[Epub]     CrossRef
  • Fertility‐sparing treatment for early‐stage epithelial ovarian cancer: Contemporary oncologic, reproductive and endocrinologic perspectives
    Rachel S. Mandelbaum, Maximilian Klar, Tsuyoshi Takiuchi, Liat Bainvoll, Shinya Matsuzaki, Richard J. Paulson, Koji Matsuo
    Journal of Obstetrics and Gynaecology Research.2020; 46(8): 1263.     CrossRef
  • Impact of uterus‐preserving surgery on Stage I primary mucinous epithelial ovarian carcinoma: A multi‐institutional study with propensity score‐weighted analysis
    Masato Yoshihara, Hiroaki Kajiyama, Satoshi Tamauchi, Shohei Iyoshi, Akira Yokoi, Shiro Suzuki, Michiyasu Kawai, Tetsuro Nagasaka, Kunihiko Takahashi, Shigeyuki Matsui, Fumitaka Kikkawa
    International Journal of Gynecology & Obstetrics.2020; 150(2): 177.     CrossRef
  • Tumeurs épithéliales de l’ovaire : préservation de la fertilité. Article rédigé sur la base de la recommandation nationale de bonnes pratiques cliniques en cancérologie intitulée « Conduites à tenir initiales devant des patientes atteintes d’un cancer épi
    C. Uzan, B. Courbiere, N. Chabbert-Buffet
    Gynécologie Obstétrique Fertilité & Sénologie .2019; 47(2): 180.     CrossRef
  • Mucinous Ovarian Carcinoma
    Dan L. Longo, Philippe Morice, Sebastien Gouy, Alexandra Leary
    New England Journal of Medicine.2019; 380(13): 1256.     CrossRef
  • Early stage mucinous ovarian cancer: A review
    Erin K. Crane, Jubilee Brown
    Gynecologic Oncology.2018; 149(3): 598.     CrossRef
  • Results of Fertility-Sparing Surgery for Expansile and Infiltrative Mucinous Ovarian Cancers
    Sebastien Gouy, Marine Saidani, Amandine Maulard, Slim Bach-Hamba, Enrica Bentivegna, Alexandra Leary, Patricia Pautier, Mojgan Devouassoux-Shisheboran, Catherine Genestie, Philippe Morice
    The Oncologist.2018; 23(3): 324.     CrossRef
  • Assisted reproductive techniques after fertility-sparing treatments in gynaecological cancers
    Ignacio Zapardiel, Maria Cruz, Maria D. Diestro, Antonio Requena, Juan A. Garcia-Velasco
    Human Reproduction Update.2016; 22(3): 281.     CrossRef
  • Fertility-Sparing Surgery in Epithelial Ovarian Cancer
    Enrica Bentivegna, Philippe Morice, Catherine Uzan, Sebastien Gouy
    Future Oncology.2016; 12(3): 389.     CrossRef
  • Mucinous ovarian cancer: A therapeutic review
    Wen Xu, Jack Rush, Kirsty Rickett, Jermaine I.G. Coward
    Critical Reviews in Oncology/Hematology.2016; 102: 26.     CrossRef
  • Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer
    Robert Fruscio, Lorenzo Ceppi, Silvia Corso, Francesca Galli, Tiziana Dell'Anna, Federica Dell'Orto, Daniela Giuliani, Annalisa Garbi, Stefania Chiari, Costantino Mangioni, Rodolfo Milani, Irene Floriani, Nicoletta Colombo, Cristina Maria Bonazzi
    British Journal of Cancer.2016; 115(6): 641.     CrossRef
  • Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issues
    E. Bentivegna, S. Gouy, A. Maulard, P. Pautier, A. Leary, N. Colombo, P. Morice
    Annals of Oncology.2016; 27(11): 1994.     CrossRef
  • 12,871 View
  • 109 Download
  • 36 Web of Science
  • 32 Crossref
Close layer
Patterns of Failure after Postoperative Radiation Therapy for Endometrial Carcinoma
Suzy Kim, Hong-Gyun Wu, Hyo-Pyo Lee, Soon-Beom Kang, Yong-Sang Song, Noh-Hyun Park, Sung Whan Ha
Cancer Res Treat. 2006;38(3):133-138.   Published online June 30, 2006
DOI: https://doi.org/10.4143/crt.2006.38.3.133
AbstractAbstract PDFPubReaderePub
Purpose

We tried to investigate the outcome and patterns of failure of endometrial cancer patients who were treated with surgery and postoperative radiation therapy (RT).

Materials and Methods

Eighty-three patients with endometrial cancer who received postoperative RT between May 1979 and August 2000 were included in this retrospective study. Forty-one patients received total abdominal hysterectomy, 41 patients received Wertheim's operation and 1 underwent vaginal hysterectomy. Pelvic lymph node dissection or pelvic lymph node sampling was done in 56 patients and peritoneal cytology was done in 35. All the patients were staged according to 1988 FIGO (International Federation of Gynecology and Obstetrics) staging system; 2 were stage IA, 23 were stage IB, 20 were stage IC, 4 were stage IIA, 5 were stage IIB, 9 were stage IIIA, 2 were stage IIIB and 18 were stage IIIC. The histologic diagnoses were adenocarcinoma in seventy-four patients (89%). The histologic grades were Grade 1, 2 and 3 in 21 (25%), 43 (52%) and 10 (12%) patients, respectively. All the patients received external beam RT (EBRT) with a median dose of 5,040 cGy (range: 4,500~5,075 cGy) to the whole pelvis. Five patients with pathologically confirmed paraaortic lymph node metastasis received 4500 cGy to the paraaortic lymph nodes. Fifteen patients received low-dose intracavitary brachytherapy after their EBRT. A total dose of 7,500~9,540 cGy (median dose: 8511) was prescribed to the vaginal surface.

Results

Overall, 11 patients (13%) experienced disease relapse: 4 with initial stage I or II disease and 7 with initial stage III disease. Among the 54 stage I or II patients, 1 (2%) relapsed in the pelvis only, 2 (4%) relapsed in the vagina and distant organs, and 1 (2%) relapsed in the paraaortic lymph nodes (PANs). Among the 29 stage III patients, 1 (3%) relapsed in the vagina. The most common sites of failure for the stage III patients were the peritoneum (3 patients, 10%), PANs (2 patients, 7%), and lung (2 patients, 7%). With a median follow-up period of 86 months, the overall survival (OS) and disease-free survival (DFS) rates at 5 years were 87% for both. The five-year DFS rate was 93%, 100% and 74% for the stage I, II and III patients, respectively. Three patients experienced severe radiation-related late complications: RTOG (Radiation Therapy Oncology Group) grade 3 radiation cystitis was seen in one patient, and grade 3 bowel obstruction was seen in two patients.

Conclusions

Postoperative RT was useful for controlling pelvic disease. The major patterns of failure for stage III patients were peritoneal seeding and distant metastasis. Selective use of whole abdominal radiotherapy or adjuvant chemotherapy may improve the therapeutic outcome of these patients.

Citations

Citations to this article as recorded by  
  • Pattern of care and clinical outcome of patients with carcinoma endometrium and the impact of central histopathological review on management: A tertiary cancer centre experience
    Rakhi Verma, Ajeet K. Gandhi, Madhup Rastogi, Vachaspati K. Mishra, Vikas Sharma, Akash Agarwal, Saumya Shukla, Rohini Khurana, Rahat Hadi, Anoop K. Srivastava, Nuzhat Husain
    Journal of Cancer Research and Therapeutics.2024; 20(5): 1557.     CrossRef
  • Does Prophylactic Paraortic Lymph Node Irradiation Improve Outcomes in Women With Stage IIIC1 Endometrial Carcinoma?
    Jennifer Yoon, Halle Fitzgerald, Yaqun Wang, Qingyang Wang, Irina Vergalasova, Mohamed A. Elshaikh, Irina Dimitrova, Shari Damast, Jessie Y. Li, Emma C. Fields, Sushil Beriwal, Andrew Keller, Elizabeth A. Kidd, Melissa Usoz, Shruti Jolly, Elizabeth Jawors
    Practical Radiation Oncology.2022; 12(2): e123.     CrossRef
  • Efficacy of Para-Aortic Lymphadenectomy in Early-Stage Endometrioid Uterine Corpus Cancer
    Seo-Yun Tong, Jong-Min Lee, Jae-Kwan Lee, Jae Weon Kim, Chi-Heum Cho, Seok-Mo Kim, Sang-Yoon Park, Chan-Yong Park, Ki-Tae Kim
    Annals of Surgical Oncology.2011; 18(5): 1425.     CrossRef
  • Current status in the management of uterine corpus cancer in Korea
    Nan-Hee Jeong, Jong-Min Lee, Seon-Kyung Lee
    Journal of Gynecologic Oncology.2010; 21(3): 151.     CrossRef
  • 9,340 View
  • 50 Download
  • 4 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP